Business
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial The Company will host a conference call and webcast toda
About this update from Biomx Inc.
[{"type":"image","alt":"BiomX","displaySize":"","headline":null,"caption":"BiomX","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/9247c1c78e1902ad0f285e23134d4eef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ThyHzYo_ZJB5tg4FLK0lug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9247c1c78e1902ad0f285e23134d4eef","width":300,"height":81}},"lazy":false},{"type":"text","content":"In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO)","length":148,"tagName":"p"},{"type":"text","content":"BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026","length":90,"tagName":"p"},{"type":"text","content":"In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial","length":203,"tagName":"p"},{"type":"text","content":"The Company will host a conference call and webcast today at 2:00 PM ET","length":71,"tagName":"p"},{"type":"text","content":"NESS ZIONA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced financial results for the first quarter ended March 31, 2025, and provided program and business updates.","length":356,"tagName":"p"},{"type":"text","content":"“The first quarter of 2025 was a period of exceptional progress for BiomX, both on the corporate front and across our clinical pipeline,” said Jonathan Solomon, Chief Executive Officer of BiomX. “The strength of the positive Phase 2 results from our BX211 program in diabetic foot osteomyelitis exceeded our expectations and received resounding endorsement from key opinion leaders and industry experts. These positive results represent a significant milestone for the field of bacteriophage therapy and further reinforce our platform’s potential to address serious, resistant infections. Notably, the BX211 program has been supported to date by approximately $40 million in non-dilutive funding from the U.S. Defense Health...